Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 5

Habitual coffee consumption and blood pressure: An epidemiological perspective

Authors Johanna M Geleijnse

Published Date August 2008 Volume 2008:4(5) Pages 963—970

DOI http://dx.doi.org/10.2147/VHRM.S3055

Published 5 August 2008

Johanna M Geleijnse

Division of Human Nutrition, Wageningen University, The Netherlands

Abstract: This paper summarizes the current epidemiological evidence on coffee consumption in relation to blood pressure (BP) and risk of hypertension. Data from crosssectional studies suggest an inverse linear or U-shaped association of habitual coffee use with BP in different populations. Prospective studies suggest a protective effect of high coffee intake (4 or more cups per day) against hypertension, mainly in women. Furthermore, the risk of hypertension may be lower in coffee abstainers. Randomized controlled trials, which are mostly of short duration (1–12 weeks), have shown that coffee intake around 5 cups per day causes a small elevation in BP (∼2/1 mmHg) when compared to abstinence or use of decaffeinated coffee. With regard to underlying biological mechanisms, most research has been devoted to BP-raising effects of caffeine. However, there are many other substances in coffee, such as polyphenols, soluble fi bre and potassium, which could exert a beneficial effect in the cardiovascular system. Although the precise nature of the relation between coffee and BP is still unclear, most evidence suggests that regular intake of caffeinated coffee does not increase the risk of hypertension.

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Muscular effects of statins in the elderly female: a review

Bhardwaj S, Selvarajah S, Schneider EB

Clinical Interventions in Aging 2013, 8:47-59

Published Date: 18 January 2013

Implications for breast cancer dormancy in other areas of medicine

Rameshwar P

Breast Cancer: Targets and Therapy 2012, 4:193-195

Published Date: 5 December 2012

Lactose intolerance: diagnosis, genetic, and clinical factors

Mattar R, Mazo DF, Carrilho FJ

Clinical and Experimental Gastroenterology 2012, 5:113-121

Published Date: 5 July 2012

NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo

Harada M, Iwata C, Saito H, Ishii K, Hayashi T, Yashiro M, Hirakawa K, Miyazono K, Kato Y, Kano MR

International Journal of Nanomedicine 2012, 7:2713-2727

Published Date: 31 May 2012

Integrins and extracellular matrix in mechanotransduction

Ramage L

Cell Health and Cytoskeleton 2012, 4:1-9

Published Date: 28 December 2011

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations

Balkundi S, Nowacek AS, Veerubhotla RS, Chen H, Martinez-Skinner A, Roy U, Mosley RL, Kanmogne G, Liu X, Kabanov AV, Bronich T, McMillan J, Gendelman HE

International Journal of Nanomedicine 2011, 6:3393-3404

Published Date: 20 December 2011

Microscope-controlled glass bead blasting: a new technique

Peter Kotschy, Sascha Virnik, Doris Christ, et al

Clinical, Cosmetic and Investigational Dentistry 2011, 3:9-16

Published Date: 20 January 2011

Mechanisms of endothelial dysfunction in obstructive sleep apnea

Amy Atkeson, Sanja Jelic

Vascular Health and Risk Management 2008, 4:1327-1335

Published Date: 7 October 2008

Kennedy space center cardiovascular disease risk reduction program evaluation

Kristine S Calderon, Charles Smallwood, David A Tipton

Vascular Health and Risk Management 2008, 4:421-426

Published Date: 6 May 2008

Nebivolol in the treatment of chronic heart failure

Angie Veverka, Jennifer L Salinas

Vascular Health and Risk Management 2007, 3:647-654

Published Date: 20 November 2007